SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49( 3): 466-5; discussion 75-77.
  • 2
    Lee CT, Dunn RL, Ingold C, Montie JE, Wood DP Jr. Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology. 2007; 69( 6): 1068-1072.
  • 3
    Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004; 45( 3): 292-296.
  • 4
    Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007; 178( 6): 2314-2330.
  • 5
    Hollenbeck BK, Ye Z, Dunn RL, Montie JE, Birkmeyer JD. Provider treatment Intensity and outcomes for patients with early stage bladder cancer. J Natl Cancer Inst. 2009; 101: 571-580.
  • 6
    Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000; 163( 4): 1124-1129.
  • 7
    Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171( 6 pt 1): 2186-2190, quiz 435.
  • 8
    Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl. 1995; 172: 33-36.
  • 9
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Medical Care. 2002; 40( suppl 8): IV-3-18.
  • 10
    Surveillance, Epidemiology, and End Results (SEER) Program. Number of persons by race and hispanic ethnicity for SEER Participants (2000 census data). Available at: http://seer.cancer.gov/registries/data.html. Accessed December 30, 2008.
  • 11
    Greene F, Page E, Fleming I. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verley; 2002.
  • 12
    Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002; 40( suppl 8): IV-104-117.
  • 13
    Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000; 163( 1): 60-61; discussion 61-2.
  • 14
    Alibhai SM, Leach M, Tomlinson GA, Krahn MD, Fleshner NE, Naglie G. Is there an optimal comorbidity index for prostate cancer? Cancer. 2008; 112( 5): 1043-1050.
  • 15
    Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007; 109( 9): 1777-1783.
  • 16
    Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med. 2001; 345( 2): 99-106. Comment in: N Engl J Med. 2001; 345: 134-6.
  • 17
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53( 12): 1258-1267.
  • 18
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008; 54( 2): 303-314.
  • 19
    Scher H, Bahnson R, Cohen S, et al. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park). 1998; 12( 7A): 225-271.
  • 20
    Diamond GA, Kaul S. The disconnect between practice guidelines and clinical practice—stressed out. Jama. 2008; 300( 15): 1817-179.
  • 21
    Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003; 21( 18): 1315-1330.
  • 22
    Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19( 3): 666-675.
  • 23
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349( 9): 859-866.
  • 24
    Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. Jama. 2006; 295( 7): 801-808.
  • 25
    Schmoor C, Caputo A, Schumacher M. Evidence from nonrandomized studies: a case study on the estimation of causal effects. Am J Epidemiol. 2008; 167( 9): 1120-1129.
  • 26
    Herr H, Konety B, Stein J, Sternberg CN, Wood DP, Jr. Optimizing outcomes at every stage of bladder cancer: Do we practice it? Urol Oncol. 2009; 27( 1): 72-74.
  • 27
    Tu HT, Hargraves JL. Seeking health care information: most consumers still on the sidelines. Issue Brief Cent Stud Health Syst Change. 2003;( 61): 1-4.